One Standard, Many Markets: What FDA, EMA, and PMDA Actually Agree On
ISPOR 2026 reflections: AI, access, and the evolving role of RWE in oncology
From data to decisions: What “regulatory-grade” real-world evidence actually requires
Informing global evidence strategies with real-world data across multiple geographies
Behind the Research: An Exploration of Real-World Data's Ability to Support Adverse Event Surveillance at ISPOR Europe
From Obligation to Opportunity: Accelerating Safety Evidence Using Digital and Pragmatic Solutions
How to incorporate pragmatic design elements into your clinical studies